References
1. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2013 Aug 22;369(8):699–710.
2. Fazio VW, Kiran RP, Remzi FH, Coffey JC, Heneghan HM, Kirat HT, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013 Apr;257(4):679–85.
3. Barnes EL, Herfarth HH, Sandler RS, Chen W, Jaeger E, Nguyen VM, et al. Pouch-Related Symptoms and Quality of Life in Patients with Ileal Pouch–Anal Anastomosis. Inflamm Bowel Dis. 2017 Jul;23(7):1218–24.
4. Landy J, Al-Hassi HO, McLaughlin SD, Knight SC, Ciclitira PJ, Nicholls RJ, et al. Etiology of pouchitis*. Inflamm Bowel Dis. 2012 Jun;18(6):1146–55.
5. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003 May;124(5):1202–9.
6. Gionchetti P, Calabrese C, Lauri A, Rizzello F. The therapeutic potential of antibiotics and probiotics in the treatment of pouchitis. Expert Rev Gastroenterol Hepatol. 2015 Sep 2;9(9):1175–81.
7. Ribaldone DG, Resegotti A, Astegiano M. The therapy of chronic pouchitis. Minerva Gastroenterol Dietol. 2019 Jan 4;
8. GIONCHETTI P, RIZZELLO F, POGGIOLI G, PIERANGELI F, LAURETI S, MORSELLI C, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther. 2007 Feb 28;25(10):1231–6.
9. Gionchetti P, Amadini C, Rizzello F, Venturi A, Campieri M. Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther. 2002 Jul;16 Suppl 4:13–9.
10. Acosta BM, García-Bosch O, Souto R, Mañosa M, Miranda J, García-Sanchez V, et al. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: A multicenter study. Inflamm Bowel Dis. 2012 May;18(5):812–7.
11. Barreiro-de Acosta M, García-Bosch O, Gordillo J, Mañosa M, Menchén L, Souto R, et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab. Eur J Gastroenterol Hepatol. 2012 Jul;24(7):756–8.
12. Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998 Jun;85(6):800–3.
13. Hammer HF. Gut Microbiota and Inflammatory Bowel Disease. Dig Dis. 2011;29(6):550–3.
14. Schmid M, Frick J-S, Malek N, Goetz M. Successful treatment of pouchitis with Vedolizumab, but not fecal microbiota transfer (FMT), after proctocolectomy in ulcerative colitis. Int J Colorectal Dis. 2017 Apr 17;32(4):597–8.
15. Coletta M, Paroni M, Caprioli F. Successful Treatment With Vedolizumab in a Patient With Chronic Refractory Pouchitis and Primary Sclerosing Cholangitis. J Crohn’s Colitis. 2017 Dec 4;11(12):1507–8.
16. Mir F, Yousef MH, Partyka EK, Tahan V. Successful treatment of chronic refractory pouchitis with vedolizumab. Int J Colorectal Dis. 2017 Oct 11;32(10):1517–8.
17. Martins D, Ministro P, Silva A. Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab. GE - Port J Gastroenterol. 2018 Nov;25(6):340–1.
18. Orfanoudaki E, Foteinogiannopoulou K, Koutroubakis IE. Use of vedolizumab in a patient with chronic and refractory pouchitis. Ann Gastroenterol. 2018;31(3):379.
19. Bär F, Kühbacher T, Dietrich NA, Krause T, Stallmach A, Teich N, et al. Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis. Aliment Pharmacol Ther. 2018 Mar;47(5):581–7.
20. Philpott J, Ashburn J, Shen B. Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis. Inflamm Bowel Dis. 2017 Jan;23(1):E5–6.
21. Singh A, Khan F, Lopez R, Shen B, Philpott J. Sa1829 - Vedolizumab for Chronic Antibiotic Refractory Pouchitis. Gastroenterology. 2018 May;154(6):S-411.
22. Segal JP, Penez L, Mohsen Elkady S, Worley GHT, McLaughlin SD, Mullish BH, et al. Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study. Scand J Gastroenterol. 2018 Sep 29;1–8.